CTHRepealedLegislation
National Health (Weighted average disclosed price – first transitional disclosure cycle) Determination 2011 (No. PB 81 of 2011)
5Weighted average disclosed price for brands of pharmaceutical items – unadjusted price reduction is at least 10%
Start here
Get a plain-English read of 5
Turn the raw legal text into a practical explanation grounded in National Health (Weighted average disclosed price – first transitional disclosure cycle) Determination 2011 (No. PB 81 of 2011).
5 Weighted average disclosed price for brands of pharmaceutical items – unadjusted price reduction is at least 10%
For subsection 99ADB(4) of the Act, the weighted average disclosed price specified in column 3 of an item in Schedule 1 is the weighted average disclosed price for the brand of pharmaceutical item specified in column 2 of the same item in Schedule 1.